- Home
- ARCT vs ALDX Comparison
ARCT vs ALDX Comparison
Compare ARCT & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- ALDX
- Stock Information
- Founded
- ARCT 2013
- ALDX 2004
- Country
- ARCT United States
- ALDX United States
- Employees
- ARCT N/A
- ALDX N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- ALDX Health Care
- Exchange
- ARCT Nasdaq
- ALDX Nasdaq
- Market Cap
- ARCT 320.8M
- ALDX 342.3M
- IPO Year
- ARCT N/A
- ALDX 2014
- Fundamental
- Price
- ARCT $17.32
- ALDX $5.39
- Analyst Decision
- ARCT Strong Buy
- ALDX Strong Buy
- Analyst Count
- ARCT 10
- ALDX 2
- Target Price
- ARCT $50.88
- ALDX $9.50
- AVG Volume (30 Days)
- ARCT 536.4K
- ALDX 772.4K
- Earning Date
- ARCT 11-06-2025
- ALDX 11-06-2025
- Dividend Yield
- ARCT N/A
- ALDX N/A
- EPS Growth
- ARCT N/A
- ALDX N/A
- EPS
- ARCT N/A
- ALDX N/A
- Revenue
- ARCT $122,122,000.00
- ALDX N/A
- Revenue This Year
- ARCT N/A
- ALDX N/A
- Revenue Next Year
- ARCT $31.09
- ALDX $43.00
- P/E Ratio
- ARCT N/A
- ALDX N/A
- Revenue Growth
- ARCT N/A
- ALDX N/A
- 52 Week Low
- ARCT $8.04
- ALDX $1.14
- 52 Week High
- ARCT $25.88
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- ARCT 54.49
- ALDX 45.98
- Support Level
- ARCT $17.38
- ALDX $5.48
- Resistance Level
- ARCT $18.69
- ALDX $5.88
- Average True Range (ATR)
- ARCT 1.00
- ALDX 0.27
- MACD
- ARCT -0.11
- ALDX -0.07
- Stochastic Oscillator
- ARCT 44.23
- ALDX 1.87
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.